Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients

伦瓦提尼 阿替唑单抗 医学 贝伐单抗 内科学 肝细胞癌 肿瘤科 不利影响 人口 无进展生存期 胃肠病学 癌症 无容量 化疗 索拉非尼 免疫疗法 环境卫生
作者
YEN-HAO CHEN,Yen‐Yang Chen,JING-HOUNG WANG,CHAO-HUNG HUNG
出处
期刊:Anticancer Research [Anticancer Research USA Inc.]
卷期号:43 (3): 1377-1384 被引量:2
标识
DOI:10.21873/anticanres.16286
摘要

Background/Aim: This study aimed to assess the clinical impact of lenvatinib after disease progression on atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC). Patients and Methods: A total of 14 patients who received lenvatinib after failure of atezolizumab plus bevacizumab and all patients were classified as having a Barcelona Clinic Liver Cancer stage C. Six patients had macrovascular invasion, and a liver occupation rate of >50% was reported in seven patients. The Kaplan–Meier method was performed to analyze the cumulative survival, while log-rank test was used to detect the differences. The dose of lenvatinib was determined based on body weight. Results: The participants’ responses to lenvatinib treatment were as follows: 21.4% achieved partial response (PR), while 35.7% had a stable disease, with a disease control rate of 57.1%. The median progression-free survival (PFS) and overall survival (OS) were 4.2 months and 8.3 months, respectively; the median PFS and OS were 6.7 months and 10.5 months in the PR group. No significant difference was observed in the median PFS and OS between patients with and without macrovascular invasion or liver occupation rate of >50%. Most of the adverse events (AEs) were categorized as grade 1-2; all patients tolerated the AEs, and no drug-related mortality was reported. Additionally, half of the population underwent subsequent therapy after progression on lenvatinib treatment. Conclusion: Lenvatinib is effective and can be safely used as second-line systemic therapy after progression on atezolizumab plus bevacizumab in patients with advanced HCC in real-world clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yanghao完成签到,获得积分10
刚刚
YW完成签到,获得积分10
1秒前
我想@科研完成签到,获得积分10
1秒前
2秒前
欣一发布了新的文献求助10
2秒前
3秒前
11发布了新的文献求助10
4秒前
嗯呐完成签到,获得积分10
4秒前
5秒前
隔窗听雨发布了新的文献求助10
5秒前
5秒前
yyyyy发布了新的文献求助10
6秒前
liuying完成签到,获得积分10
6秒前
乐观忆灵应助胡1111采纳,获得10
6秒前
被动科研应助二三采纳,获得10
6秒前
7秒前
s0x0y0发布了新的文献求助10
8秒前
8秒前
Jasper应助yinying采纳,获得10
8秒前
Bailan发布了新的文献求助10
8秒前
9秒前
好困应助快乐荔枝采纳,获得20
9秒前
顾矜应助雨碎寒江采纳,获得10
9秒前
靓丽访枫发布了新的文献求助10
9秒前
10秒前
10秒前
万能图书馆应助老实新筠采纳,获得10
10秒前
温衡的言希完成签到,获得积分10
10秒前
korchid发布了新的文献求助20
11秒前
沙尘飞扬完成签到,获得积分10
11秒前
11秒前
小曦仔完成签到,获得积分10
12秒前
12秒前
个十百千萬完成签到,获得积分10
12秒前
WindWalker完成签到,获得积分10
13秒前
13秒前
小白科研发布了新的文献求助10
13秒前
研友_LNMmW8发布了新的文献求助10
13秒前
假面绅士发布了新的文献求助10
14秒前
Orange应助阿航采纳,获得10
17秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3082954
求助须知:如何正确求助?哪些是违规求助? 2736245
关于积分的说明 7540502
捐赠科研通 2385654
什么是DOI,文献DOI怎么找? 1265037
科研通“疑难数据库(出版商)”最低求助积分说明 612909
版权声明 597693